Adaptimmune Therapeutics (NASDAQ:ADAP) Director Sells $146,717.94 in Stock

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Director Ali Behbahani sold 14,671,794 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $0.01, for a total transaction of $146,717.94. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Ali Behbahani also recently made the following trade(s):

• On Friday, August 15th, Ali Behbahani sold 4,828,206 shares of Adaptimmune Therapeutics stock. The stock was sold at an average price of $0.01, for a total transaction of $48,282.06.

Adaptimmune Therapeutics Price Performance

Shares of Adaptimmune Therapeutics stock opened at $0.0571 on Thursday. Adaptimmune Therapeutics PLC has a twelve month low of $0.0520 and a twelve month high of $1.33. The company has a quick ratio of 1.29, a current ratio of 1.52 and a debt-to-equity ratio of 4.24. The company has a 50-day simple moving average of $0.20 and a two-hundred day simple moving average of $0.30. The stock has a market capitalization of $15.13 million, a price-to-earnings ratio of -0.09 and a beta of 2.18.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. Adaptimmune Therapeutics had a negative net margin of 260.82% and a negative return on equity of 163.73%. The business had revenue of $13.68 million during the quarter, compared to analysts’ expectations of $11.04 million. Analysts forecast that Adaptimmune Therapeutics PLC will post -0.14 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on ADAP shares. Guggenheim cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 29th. Wells Fargo & Company dropped their price objective on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 14th. Mizuho cut shares of Adaptimmune Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $1.50 to $0.50 in a research note on Thursday, June 26th. Barclays dropped their target price on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an “underweight” rating for the company in a research report on Wednesday, May 14th. Finally, Wall Street Zen started coverage on shares of Adaptimmune Therapeutics in a research report on Friday, May 16th. They issued a “buy” rating for the company. One analyst has rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $1.35.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC raised its position in shares of Adaptimmune Therapeutics by 52.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock valued at $1,361,000 after buying an additional 869,949 shares in the last quarter. Two Sigma Advisers LP grew its holdings in shares of Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 58,787 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Adaptimmune Therapeutics by 87.7% during the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 152,780 shares during the last quarter. Two Seas Capital LP bought a new stake in shares of Adaptimmune Therapeutics during the 4th quarter valued at approximately $7,992,000. Finally, Long Focus Capital Management LLC grew its holdings in shares of Adaptimmune Therapeutics by 54.1% during the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock valued at $11,040,000 after purchasing an additional 7,194,503 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.